MORAb-003-011: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
A study for women with ovarian cancer using study drug farletuzumab
Sponsor: Morphotek
Enrolling: Female Patients Only
IRB Number: AAAP0961
U.S. Govt. ID: NCT02289950
Contact: Reena Vattakalam: 212-342-6895 /
Additional Study Information: This study will only include women who have platinum sensitive relapsed epithelial ovarian cancer meaning your ovarian cancer did not return for at least 6 months after your first treatment with chemotherapy containing platinum (carboplatin or cisplatin). This research is being done to find out if carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), chemotherapies (anticancer drugs) that are used to treat ovarian cancer, work better alone or when given with a study drug called farletuzumab. Whether you will be treated with carboplatin/paclitaxel or carboplatin/PLD as your chemotherapy regimen, will be the decision of your study doctor. The samples (tumor tissue, blood, and urine) obtained during this study may be used to help develop diagnostic tests that may enhance the ability of doctors to detect ovarian cancer, guide the therapy and care of women diagnosed with ovarian cancer, and predict which therapies may be most successful or should be avoided in women diagnosed with ovarian cancer, and other possible uses.
This study is closed
Jason Wright, MD
Do You Qualify?
Have you been diagnosed with ovarian cancer? Yes No
Are you currently breast-feeding, pregnant, or likely to become pregnant during the study? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Reena Vattakalam